All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-12-21T09:22:10.000Z

ASH 2017 | High response rates seen with CTL019 in R/R DLBCL: Juliet trial primary analysis

Dec 21, 2017
Share:

Bookmark this article

The 59th Annual Meeting & Exposition of the American Society of Hematology (ASH) took place in Atlanta, GA, on December 9–12, 2017. On Monday December 11th, an oral abstract session was held on “Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Immune-Based Therapeutic Approaches”. This session was moderated by Robert A Baiocchi, Ohio State University and Lode J Swinnen, Johns Hopkins University.

Abstract #577 was presented during this session titled “Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma” by Stephen J. Schuster, Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, and colleagues. In the summary below, data from the live session at ASH is used and therefore may supersede information in the pre-published Abstract.

Study Highlights

  • 147 eligible patients (median age = 56 years (22–76)) were included in the study who were diagnosed with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), progressed after more than two lines of chemotherapy and were ineligible for autologous stem cell transplant (auto-SCT)
  • Patients received a single dose infusion of CTL019 (tisagenlecleucel); median, 3.1 × 108 (range, 0.1-6.0 × 108) cells
  • CAR-T cells were centrally manufactured and delivered to patients at 27 centers in 10 different countries across 4 continents. The logistics of this involved using cryopreserved apheresis, central production facilities and a global supply chain, demonstrating feasibility of treatment distribution
  • The primary endpoint was best overall response rate (ORR) including complete response (CR) and partial response (PR) and was evaluated by an independent review committee (IRC)
  • At ≥3 months’ follow-up
    • Best ORR = 53.1% (95% CI, 42% to 64%; P < 0.0001)
    • CR = 39.5% and PR = 13.6%
  • At 3 months’ follow-up
    • CR = 32% and PR = 6%
  • 6 months’ follow-up of 46 patients
    • CR = 30% and PR = 7%
  • Median duration of response was not reached
    • 6-month probability of being relapse free was 73.5% (95% CI, 52.0% to 86.6%)
  • Median overall survival was not reached
    • 6-month probability of overall survival was 64.5% (95% CI, 51.5% to 74.8%

Safety

  • Most frequent grade 3 or 4 adverse events (AEs) included; cytokine release syndrome (58%), cytopenias lasting more than 28 days (27%) and infections (20%)
  • 3 patient deaths were reported that were considered unrelated to treatment

The JULIET study demonstrated high durable responses in patients with R/R DLBCL treated with tisagenlecleucel. The authors concluded that this data should support global regulatory submissions for this treatment in 2018. CTL019 received breakthrough therapy designation for adults with R/R DLBCL on 18th April 2017 by the U.S. Food and Drug Administration (FDA).

  1. Schuster S. et al. Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Oral Abstract #577: ASH 59th Annual Meeting and Exposition, Atlanta, GA.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox